ARCHIVE

DECEMBER 2005 MEETING

The December meeting of the London Regenerative Medicine Network will be held in the evening of Monday 12th December at King's College London (New Hunt's House Lecture Theatre 2, Guy's Hospital campus at London Bridge, London SE1). The meeting will include an update on The UK Stem Cell Foundation by its Chief Executive, David Macauley and presentations by two leading players in the UK regenerative medicine world - Prof. Richard Oreffo and his mesenchymal stem cell research which has just entered the clinic and Dr. Mark Lewis who will discuss his soft tissue regeneration research plus his experience as a Scientific Consultant to Isolagen Inc, a pioneering American regenerative medicine company who over the past two years has treated more than 8,500 patients with autologous cell therapies
.


David Macauley - Chief Executive - UK Stem Cell Foundation

In February 2005, a group of high profile scientists and business people launched an initiative to establish a £100 million foundation in the UK to support stem cell research and its applications. The purpose of the Foundation is to ensure a speedy transfer from the laboratory bench to the bedside. To attain this goal, the Foundation plans initially to directly fund promising clinical projects in UK medical schools, universities and hospitals. This will be achieved by providing support to enable translational research studies and clinical trials to advance; and by promoting a collaborative dialogue amongst the stem cell research community. The creation of the Foundation has been personally endorsed by the Prime Minister and the Chancellor of the Exchequer, as well as by the Royal Society of Medicine, MRC and BBSRC, and by twenty leading research universities, including Cambridge, Imperial, Oxford and UCL.

David has very kindly agreed to bring us all up to date with the Foundation's progress.

http://news.bbc.co.uk/1/hi/sci/tech/4248079.stm

http://www.sundayherald.com/48064


Prof. Richard Oreffo - University of Southampton

Richard leads the tissue engineering programme at Southampton. He has extensive expertise in skeletal biology and the mechanisms involved in mesenchymal stem cell differentiation. In 2001 he was recognised with the Maxime Hanns award for collaborative research in Bone Tissue Engineering, appointed to a Senior Lectureship in 2002 and to a Readership and Personal Chair in 2004.

Richard's group's research is primarily centred on:
i) development of unique tissue engineering approaches for new cartilage and bone formation for orthopaedic application using human mesenchymal stem cells
ii) elucidating the role of fetal programming as a consequence of maternal nutritional challenge on mesenchymal stem cell differentiation, activity, potential and bone function with age.

The group is currently developing strategies to couple stem cell technology with biomimetic scaffolds in close collaboration with biomaterials and tissue engineering groups in the UK as well as international collaborations in Germany and the USA. Recently his research has just entered the clinical phase.

http://www.mesenchymalstemcells.org

www.bbsrc.ac.uk/media/pressreleases/05_09_29_gene_delivery.html

http://news.bbc.co.uk/2/hi/uk_news/england/2699695.stm



Dr. Mark Lewis - UCL Eastman Dental Institute, London

Mark has two hats! Not only being Director of Research Operations at the Eastman Dental Institute, he is also a Scientific Consultant to Isolagen Inc. Isolagen, founded in 1995 and located in Houston, Texas, has become an emerging force in regenerative medicine by specialising in the development and commercialisation of its autologous cellular system technology. The "Isolagen Process" represents a unique breakthrough in autologous cell therapy technology including potential applications in a number of areas such as cosmetic dermatology, cosmetic surgery, periodontal disease, and reconstructive dentistry. To date over 8,500 patients have been treated with Isolagen produced autologous cell therapies, the patient's cells being processed in their London laboratories. In what is a rapidly changing regulatory landscape, Mark's experiences with Isolagen have ranged from dealing with the media to suggested changes to their processes through to UCL projects funded by the company.

http://www.eastman.ucl.ac.uk/staff/mlewis.html

http://www.isolagen.com/


This meeting is free of charge to everyone through the generous sponsorship of GlaxoSmithKline plus the kind assistance of the London Biotechnology Network.

PLEASE NOTE THAT DUE TO LECTURE THEATRE SEATING CAPACITY + CATERING ARRANGEMENTS, IF YOU WISH TO ATTEND THIS EVENT YOU MUST REGISTER, OTHERWISE UNFORTUNATELY YOU WILL NOT BE ABLE TO GAIN ADMISSION. Seat allocation is on a first come first served basis. If you wish to attend, all that is required, is to email the Network Secretary.


Agenda:

18.00 - Registration over tea and coffee

18.30 - Welcome by Mr. Chris Mason (UCL) - Co-organiser of the Network

18.35 - Presentation 1 - "Facing the future: experiences at the academic/industry interface" - Dr. Mark Lewis - Director of Research Operations - Eastman Dental Institute

19.05 - Q+A Session

19.10 - Presentation 2 - "Bridging the gap: restoring ageing bones using bone tissue engineering strategies" - Prof. Richard Oreffo - University of Southampton

19.40 - Q+A Session

19.45 - Up date on The UK Stem Cell Foundation - David Macauley - Chief Executive - UK Stem Cell Foundation

20.00 - Closing remarks including news on the launch of the new journal "Regenerative Medicine" - Dr. Stephen Minger (King's) - Co-organiser of the Network

20.10 - 22.00 - Networking reception - enjoy a glass of wine or two...

Please only respond if you can definitely make the meeting. Responses must go to the Network Secretary.

We look forward to seeing everyone on Monday 12th December for our final event of 2005!

Stephen Minger + Chris Mason
Co-organisers, London Regenerative Medicine Network.
www.regenmednetwork.com



PRINCIPLE SPONSORS


Pasted Graphic


Guy's, King's and St Thomas' Annual Fund



London Regenerative Medicine Network

"Bringing the regenerative medicine, stem cell and tissue engineering community together..."